FDA Approves GSK's Blenrep for Multiple Myeloma Treatment, Marking a Market Return on October 24, 2025 Approved Blenrep bortezomib dexamethasone Multiple Myeloma SmithKline Beecham United States Food and Drug Administration +
UK approval brings GSK's Blenrep back from the brink on April 18, 2025 Antibody-Drug Conjugates Approved Blenrep Cessation of life dexamethasone DREAMM-8 Multiple Myeloma Risk UK +